Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836213 | 0.89 | TP53 (0.46) | TP53MEN1KMT2AMAPTKDM4E | |
| SCHEMBL11919100 | 0.84 | MAPT (0.39) | TP53MEN1KMT2AMAPTPKM | |
| SCHEMBL11916096 | 0.82 | ALDH1A1 (0.36) | TP53MEN1KMT2AMAPTKDM4E | |
| SCHEMBL31559833 | 0.81 | TP53 (0.52) | TP53MEN1KMT2AMAPTCNR1 | |
| SCHEMBL7014237 | 0.81 | TP53 (0.52) | TP53MEN1KMT2AMAPTCNR1 | |
| SCHEMBL16364429 | 0.80 | PIK3CD (0.38) | KDM4ECRHR2CRHR1 | |
| SCHEMBL3074451 | 0.80 | KMT2A (0.40) | TP53MEN1KMT2AMAPTKDM4E | |
| SCHEMBL12354327 | 0.79 | KMT2A (0.39) | TP53MEN1KMT2AMAPTKDM4E | |
| SCHEMBL7832280 | 0.78 | PGR (0.35) | TP53MEN1KMT2AMAPTLMNA | |
| SCHEMBL89090 | 0.77 | MAPT (0.48) | MEN1KMT2AMAPTHTTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9273077-B2 | Phosphorus derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8912330-B2 | Azaindole derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066406-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TP53 1126/4885MEN1 1313/4885KMT2A 2366/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TP53 871/4885MEN1 826/4885KMT2A 1452/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TP53 875/4885MEN1 1028/4885KMT2A 1406/4885 |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | MAP3K5, MAP3K15, MAP4K2 | TP53 685/4885MEN1 2993/4885KMT2A 1177/4885 |
| US-20110294806-A1 | AZAINDOLE DERIVATIVES AS KINASE INHIBITORS | ABL1, CDKN1A, MAP3K13 | TP53 765/4885MEN1 1089/4885KMT2A 408/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TP53 1126/4885MEN1 1313/4885KMT2A 2366/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | TP53 1126/4885MEN1 1313/4885KMT2A 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.